Could cause temporary or reversible harm; serious harm is unlikely.
Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
| Brand name | ABIRTEGA |
| Generic name | ABIRATERONE ACETATE |
| Active ingredient(s) | ABIRATERONE ACETATE |
| Distributed by / for | Hikma Pharmaceuticals USA INC. |
| NDC | 82249-011-12 |
| Full product label | Abirtega (abiraterone acetate) USP, 250 mg, 120-count bottles, Rx only, Rx only, Mfd for: Hikma Pharmaceuticals USA Inc., Berkley Heights, NJ 07922 USA by: Arab Pharmaceuticals Manufacturing PSC PO Box 41, Sahab-Jordon, NDC 82249-011-12. |
| Recalling firm | Hikma Pharmaceuticals USA INC. |
| Distribution | Nationwide within the United States |
| Quantity | 2136 bottles |
| Recall initiated | 2026-10-06 |
| Report date | 2026-10-28 |
| Recall completed | — |
| Recall number | D-0076-2027 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗